Kyle Hogan
Over the past year and a half, the decentralized trial (DCT) model has helped many studies stay on track amid the disruption of the COVID-19 pandemic. In many ways, the pandemic has served as a real-world case study demonstrating this model’s advantages. And yet, the pandemic was not the genesis of decentralized trials. Decentralized trials …
Read moreHow does the DCT model increase equity in clinical trials?
As the industry continues embracing the idea of the decentralized clinical trial (DCT), my thoughts always return to a breast-cancer survivor I heard speak at a conference several years ago. While I don’t remember her name or the trial she had participated in, I was struck by the fact that she had joined the trial not to alleviate symptoms or enhance her quality of life.
Read moreBetter experience, better results: 5 must-haves for any decentralized trial
Social media companies make big investments to increase people’s engagement with their platforms. They employ all manner of tactics and techniques to make us spend more time viewing their content. The reason is simple: The higher the engagement, the more advertising revenue they can generate. In the clinical trial space, enhancing engagement of patients is …
By: Kyle Hogan, Executive Vice President, Strategy, Datacubed Health The COVID-19 pandemic created tectonic shifts across industries – including clinical trials. The inability to rely on traditional face-to-face interactions and paper-based processes propelled trials into the digital age. Industry thought leaders seem to agree that there’s no going back. (The sentiment even has a hashtag: …